Presentations

xPloration^®: Simplifying Deep Antibody Mining for Maximum Impact

Admin / May 13, 2025

xPloration^®: Simplifying Deep Antibody Mining for Maximum Impact Read More »

Deep Screening in Harmony with AI for Bispecific Antibody Discovery

Admin / May 15, 2024

Deep Screening in Harmony with AI for Bispecific Antibody Discovery Read More »

Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep

Admin / December 15, 2023

Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep Read More »

OmnidAb: Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding

Admin / December 14, 2023

OmnidAb: Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding Read More »

Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding

Admin / November 15, 2023

Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding Read More »

Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep™

Admin / May 17, 2023

Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep™ Read More »

Opening the Barn Door to Antibody Discovery

admin / December 6, 2022

Opening the Barn Door to Antibody Discovery Read More »

High-Specificity OmniAb Antibodies for Bispecific Applications; 2022 World Bispecific Conference

admin / September 21, 2022

High-Specificity OmniAb Antibodies for Bispecific Applications; 2022 World Bispecific Conference Read More »

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection

admin / January 12, 2022

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection Read More »

Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2

admin / December 31, 2021

At 4-6 KD, “picobodies” represent the smallest known Ig-derived binding moiety capable of high affinity interactions with target proteins.

Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2 Read More »